Collectively, these findings across multiple independent cohorts consistently demonstrate that elevated MRPL47 expression is strongly associated with unfavorable overall survival in NSCLC patients, including those with early-stage disease. Here, MRPL47 is linked to non-small cell lung carcinoma.